Skip to ContentGo to accessibility pageKeyboard shortcuts menu
OpenStax Logo

Case Study

1.
b. Metabolic syndrome is a collection of risk factors such as hyperglycemia, hyperlipidemia, hypertension, and overweight/obesity.
2.
d. Class III obesity is 40+ kg/m2.

Review Questions

1.
d. Overweight and obesity are determined by BMI. The BMI is calculated using height and weight.
2.
b. BMI is calculated by dividing the client’s weight by their height in inches squared and multiplying by 703: 278 ÷ 69 2 = 278 ÷ 4761 = 0.0584 × 703 = 41.05 , rounded to 41.1.
3.
b. Obesity and overweight are not the same; the distinguishing factor is a person’s client’s BMI. Overweight, with a BMI of 25–29, may lead to obesity. Obesity has a higher BMI ( 30) and is associated with serious consequences.
4.
a. Benzphetamine should not be given to clients who are pregnant; clients of childbearing age should be counseled to practice strict birth control methods to avoid pregnancy while on the medication.
5.
d. Concurrent use of phenelzine, an MAOI, is contraindicated with phentermine. MAOIs should not be used 14 days before or after phenelzine use.
6.
c. The dosage of phentermine/topiramate is usually readjusted every 14 days based on effectiveness.
7.
a. The drug orlistat is available by prescription under the brand name Xenical or OTC under the brand name Alli.
8.
c. Orlistat is not systemically absorbed and does not affect the cardiovascular and neurological systems. Common side effects are specific to the GI system—abdominal discomfort, flatus, nausea, oily rectal discharge, fecal urgency, fatty stool, and diarrhea.
9.
d. Bupropion is an antidepressant, and naltrexone is an opioid antagonist; when combined, they have been effective in weight management.
10.
c. Orlistat works by inhibiting the action of pancreatic lipase, an enzyme responsible for breaking down dietary fat in the small intestine. By blocking fat absorption, it reduces the number of calories absorbed from dietary fat, thus promoting weight loss.
Citation/Attribution

This book may not be used in the training of large language models or otherwise be ingested into large language models or generative AI offerings without OpenStax's permission.

Want to cite, share, or modify this book? This book uses the Creative Commons Attribution License and you must attribute OpenStax.

Attribution information
  • If you are redistributing all or part of this book in a print format, then you must include on every physical page the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
  • If you are redistributing all or part of this book in a digital format, then you must include on every digital page view the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
Citation information

© May 15, 2024 OpenStax. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution License . The OpenStax name, OpenStax logo, OpenStax book covers, OpenStax CNX name, and OpenStax CNX logo are not subject to the Creative Commons license and may not be reproduced without the prior and express written consent of Rice University.